- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07681258
A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region (ASC4Young)
ASC4Young: Real-World Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region
The aim of this study is to evaluate the real-world effectiveness and safety of asciminib among young adults with chronic myeloid leukemia (CML) across the Gulf region. The data source for this study will consist of routinely collected clinical information documented within the electronic health records (EHR) of participating centers.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Novartis Pharmaceuticals
- Telefonnummer: +41613241111
- E-post: novartis.email@novartis.com
Studera Kontakt Backup
- Namn: Novartis Pharmaceuticals
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
CML patients who initiate asciminib between 01 May 2023 and 31 May 2026 in participating centers across the Gulf region.
Beskrivning
Inclusion Criteria
- Confirmed diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP)
- Adult patients aged ≥ 18 years at the index date (or adult as defined by applicable national regulations)
- Documented exposure to asciminib during the identification period (May 2023 to May 2026)
- Provision of signed informed consent for secondary use of data, or an ethics committee-approved waiver of consent, where applicable (including for deceased patients or where data were previously collected within the EHR system)
Exclusion Criteria
- Patients who do not meet the eligibility criteria specified above
- Patients with insufficient medical record documentation to determine asciminib exposure or key study outcomes
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: RETROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Young Adults Cohort
CML patients aged ≤ 40 years at the first documented asciminib administration. |
|
Older Adults Cohort
CML patients aged > 40 years at the first documented asciminib administration. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Major Molecular Response (MMR) Rate in Young Adults
Tidsram: Approximately 12 Months
|
MMR is defined as a BCR::ABL1 level on the International Scale (BCR::ABL1 IS) ≤ 0.1%. |
Approximately 12 Months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of Adverse Events (AEs)
Tidsram: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Treatment Interruptions Due to AEs
Tidsram: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Duration of Treatment Interruptions Due to AEs
Tidsram: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Time to Treatment Discontinuation due to Adverse Events (TTDAE)
Tidsram: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 10% After 3 Months of Treatment
Tidsram: 3 months
|
3 months
|
|
|
Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 1% After 6 Months of Treatment
Tidsram: 6 months
|
6 months
|
|
|
Number of Patients With Prior Tyrosine Kinase Inhibitor (TKI) Treatment
Tidsram: Up to 12 months prior to Baseline
|
Up to 12 months prior to Baseline
|
|
|
Duration of CML at Time of Asciminib Treatment Initiation
Tidsram: Baseline
|
Baseline
|
|
|
Asciminib Starting Dose
Tidsram: Baseline
|
Baseline
|
|
|
Number of Treatment Interruptions
Tidsram: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Duration of Treatment Interruptions
Tidsram: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Patients by Reasons for Treatment Interruptions and Subsequent Treatment Switching
Tidsram: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Patients by Reason for Treatment Switch
Tidsram: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Patients by Type and Severity of AEs
Tidsram: Approximately 3, 6, and 12 months
|
Number of patients by type and severity of AEs including serious AEs and grade ≥ 3 AEs according to the Common Terminology Criteria for Adverse Events (CTCAE) v6.0. |
Approximately 3, 6, and 12 months
|
|
Incidence of AEs Leading to Dose Modifications
Tidsram: Approximately 3, 6, and 12 months
|
Dose modifications include treatment interruptions and dose reductions. |
Approximately 3, 6, and 12 months
|
|
MMR in Patients Aged > 40 years
Tidsram: Approximately 12 months
|
MMR is defined as BCR::ABL1 IS ≤ 0.1%. |
Approximately 12 months
|
|
Rate of Deep Molecular Response
Tidsram: Approximately 12 months
|
Deep molecular response includes:
|
Approximately 12 months
|
|
Number of Patients With Dose Modifications
Tidsram: Approximately 3, 6, and 12 months
|
Number of patients with dose modifications including up titration or dose reduction. |
Approximately 3, 6, and 12 months
|
|
Number of Patients by Clinicopathological Characteristics
Tidsram: Up to 12 months pre-Baseline, Baseline, and approximately 3, 6 , and 12 months post-Baseline
|
Clinicopathological characteristics include:
|
Up to 12 months pre-Baseline, Baseline, and approximately 3, 6 , and 12 months post-Baseline
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Neoplasmer
- Kronisk sjukdom
- Sjukdomsegenskaper
- Neoplasmer efter histologisk typ
- Hematologiska sjukdomar
- Leukemi, myeloid
- Benmärgssjukdomar
- Leukemi
- Myeloproliferativa störningar
- Patologiska tillstånd, tecken och symtom
- Hemiska och lymfsjukdomar
- Leukemi, Myelogen, Kronisk, BCR-ABL positiv
Andra studie-ID-nummer
- CABL001J1AE01
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .